Characterizing the immune and metabolic profiles of cutaneous T-cell lymphoma in formalin-fixed paraffin-embedded skin tissue samples

项目概要/摘要 皮肤T细胞淋巴瘤（CTCL）是一种罕见的，但潜在的破坏性皮肤恶性肿瘤。 CTCL的早期发现与积极的临床结局相关，但诊断通常很复杂 由异质性临床和组织学表现。此外，全身治疗仍然是亚- 最适合CTCL，强调需要新的治疗策略。迄今为止，大多数研究都是 在CTCL患者的血液上进行，这揭示了宿主免疫之间复杂的相互作用， 恶性T细胞和肿瘤微环境。然而，控制这种现象的分子机制 疾病的发病机制，特别是皮肤疾病的发病机制，在很大程度上仍然不明确。 拟议研究的目标是使用新技术，允许多参数，高- 福尔马林固定石蜡包埋（FFPE）皮肤组织样本的分辨率分析，以确定免疫 以及CTCL在疾病不同阶段的代谢特征。第一种技术是多路复用离子束 成像（MIBI），使用二次离子质谱法可视化多达100个金属共轭 抗体同时以纳米分辨率在FFPE组织切片中。具体来说，我将使用 MIBI定义CTCL肿瘤-宿主界面细胞的异质性和可塑性， 提高CTCL诊断和治疗的准确性。第二项技术是矩阵辅助 激光解吸/电离质谱成像（MALDI-MSI），它可以检测成千上万的 FFPE组织切片中的代谢物。具体而言，Aim II将使用MALDI-MSI来确定反射 CTCL微环境的代谢活性，从而增加对疾病的功能性了解 发病机制和揭示潜在的代谢活性治疗靶点。 总的来说，这些研究将表征分子异质性和功能复杂性， CTCL将揭示这种疾病如何逃避免疫破坏和重新编程能量- 新陈代谢.因此，这项工作有望改善以下疾病的检测、治疗和临床结果： CTCL。

PROJECT SUMMARY/ABSTRACT Cutaneous T-cell lymphoma (CTCL) is a rare, but potentially devastating malignancy of the skin. Early detection of CTCL is associated with positive clinical outcomes, but diagnosis is often complicated by the heterogeneous clinical and histological presentation. Additionally, systemic therapies remain sub- optimal for CTCL, highlighting the need for new treatment strategies. To date, most studies have been performed on blood from CTCL patients, which has revealed a complex interplay between host immunity, malignant T-cells and the tumor microenvironment. However, the molecular mechanisms that govern disease pathogenesis, especially in the skin, remain largely undefined. The goal of the proposed research is to use new technologies that allow for multi-parametric, high- resolution analyses in formalin-fixed paraffin-embedded (FFPE) skin tissue samples to define the immune and metabolic profiles of CTCL at different stages of disease. The first technology is Multiplexed Ion Beam Imaging (MIBI), which uses secondary ion mass spectrometry to visualize up to 100 metal conjugated antibodies simultaneously at nanometer resolution in FFPE tissue sections. Specifically, Aim I will use MIBI to define the heterogeneity and plasticity of cells that exist at the CTCL tumor-host interface, to improve the precision with which CTCL is diagnosed and treated. The second technology is matrix-assisted laser desorption/ionization mass spectrometry imaging (MALDI-MSI), which can detect thousands of metabolites in FFPE tissue sections. Specifically, Aim II will use MALDI-MSI to determine the reflective metabolic activity of the CTCL microenvironment, thereby adding functional insight to disease pathogenesis and revealing potential metabolically active therapeutic targets. Overall, these studies will characterize the molecular heterogeneity and functional complexity of CTCL, which will shed light on how this disease evades immune destruction and reprograms energy- metabolism. As such, this work promises to improve the detection, treatment and clinical outcomes for CTCL.